Back to Trades
Buy4
Avalyn Pharma Inc.
AVLN
Total Value
$10.0M
Net $10.0M bought
Purchases
$10.0M
2 transactions
Company Information
- Company Name
- Avalyn Pharma Inc.
- Ticker Symbol
- AVLN
- CIK
- 0001540171
Insider Information
- Role
- Insider
- Location
- REDWOOD CITY, CA
Filing Details
- Filing Date
- May 1, 2026
- Transaction Date
- May 1, 2026
- Accession Number
- 0001193125-26-201887
- Form Type
- 4
- Net Trading Amount
- $10.0M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| May 1, 2026 | Common Stock | 1,419,298 | — | C | — |
| May 1, 2026 | Common Stock | 489,486 | — | C | — |
| May 1, 2026 | Common Stock | 277,778 | $18.00 | Purchase | $5.0M |
| May 1, 2026 | Common Stock | 354,824 | — | C | — |
| May 1, 2026 | Common Stock | 489,486 | — | C | — |
| May 1, 2026 | Common Stock | 277,777 | $18.00 | Purchase | $5.0M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| May 1, 2026 | Derivative | 27,309,719 | — | C | — |
| May 1, 2026 | Derivative | 9,418,561 | — | C | — |
| May 1, 2026 | Derivative | 6,827,429 | — | C | — |
| May 1, 2026 | Derivative | 9,418,560 | — | C | — |
Footnotes
- (F1)On May 1, 2026, each share of Series C-1 Convertible Preferred Stock (the "Series C-1 Preferred Stock") automatically converted into shares of Common Stock on a one-for-19.2417 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock had no expiration date.
- (F2)The reported securities are held directly by SR One Capital Fund II Aggregator, LP ("SR One Fund II Aggregator"). SR One Capital Partners II, LP ("SR One Partners II") is the general partner of SR One Fund II, and SR One Capital Management, LLC ("SR One Capital Management") is the general partner of SR One Partners II. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Partners II, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
- (F3)On May 1, 2026, each share of Series D Convertible Preferred Stock (the "Series D Preferred Stock") automatically converted into shares of Common Stock on a one-for-19.2417 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The Series D Preferred Stock had no expiration date.
- (F4)The reported securities are held directly by AMZL, LP ("AMZL"). SR One Capital SMA Partners, LP ("SR One SMA Partners") is the general partner of AMZL, and SR One Capital Management is the general partner of SR One SMA Partners. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One SMA Partners, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.